Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMRG0A3)

Drug Name

ARQ 531 Drug Info

Synonyms

JSFCZQSJQXFJDS-QAPCUYQASA-N; UNII-JTZ51LIXN4; JTZ51LIXN4; 2095393-15-8; ARQ-531; ARQ531; SCHEMBL18770934; SCHEMBL18756744; EX-A2727; BCP29029; HY-112215; CS-0044154; HRA; (2-Chloro-4-phenoxyphenyl)(4-(((3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)amino)-7H-pyrrolo(2,3-d)pyrimidin-5-yl)methanone; 1,5-anhydro-2-{[5-(2-chloro-4-phenoxybenzene-1-carbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}-2,3,4-trideoxy-D-erythro-hexitol

Indication

Disease Entry	ICD 11	Status	REF
Hematologic tumour	2B33.Y	Phase 2	[1]

Cross-matching ID

PubChem CID: 129045720
CAS Number: CAS 2095393-15-8
TTD Drug ID: DMRG0A3

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosine-protein kinase BTK (ATK)	TTGM6VW	BTK_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Tyrosine-protein kinase BTK (ATK)	DTT	BTK	3.838	3.897	5.053	5.897

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Hematologic tumour

ICD Disease Classification

2B33.Y

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Tyrosine-protein kinase BTK (ATK)	DTT	BTK	3.54E-01	0.24	0.56

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT04728893) Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies (MK-1026-003). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)